Fast-tracking drug discovery

How we can help?

Accelerate drug discovery with Caenorhabditis elegans, a model organism uniquely suited to expedite your research. Leveraging its rapid life cycle, genetic congruence with human systems, and cost-effective maintenance, C. elegans enables swift, high-throughput screening of potential therapeutics. Its transparency allows for precise, real-time observations of biological processes, while genetic tractability permits detailed manipulation of pathways. These attributes facilitate the efficient identification and validation of novel drugs, significantly reducing the timeline from initial screening to actionable insights. Trust in C. elegans to advance your research with unparalleled speed and scientific rigor.

Success cases

  • NLX-112: Designated Orphan Drug for SCA3

    NLX-112, also known as befiradol, is a novel compound developed by Neurolixis, primarily aimed at treating L-DOPA-induced dyskinesia in Parkinson's disease. It functions as a highly selective full agonist at serotonin 5-HT1A receptors, boasting over 1000-fold selectivity compared to other receptor types.

    See Case

  • PBT2: From C. elegans Screening to Clinical Trials

    PBT2, a metal-protein attenuating compound (MPAC), was developed for Alzheimer's and Huntington's diseases. Its journey began with Caenorhabditis elegans screening, where researchers generated a transgenic strain expressing amyloid-beta (Aβ1-42).

    See Case

  • Exploring the Role of Citalopram in Treating SCA3

    Research into the treatment of Spinocerebellar Ataxia Type 3 (SCA3), a progressive neurodegenerative disorder, has yielded promising results with citalopram, a selective serotonin reuptake inhibitor (SSRI). Significantly, the initial breakthrough for citalopram’s potential in treating SCA3 was identified through unbiased small molecule screening using the model organism, Caenorhabditis elegans.

    See Case

  • Investigating TUDCA for SCA3: The Role of Caenorhabditis elegans

    The exploration of tauroursodeoxycholic acid (TUDCA) as a therapeutic for Spinocerebellar Ataxia Type 3 (SCA3) has yielded promising results, with research spearheaded by Dr. Andreia Teixeira-Castro and Dr. Patrícia Maciel at the University of Minho. A key aspect of this research was the use of Caenorhabditis elegans as an initial model organism.

    See Case

Contact us.

Email: joana.sousa@screen4health.com

Phone: +351 253604978

Address: School of Medicine University of Minho - Campus Gualtar 4710-057 Braga Portugal